All studies
Gastroenterology · Claims + National Database · US, France

Kirchgesner 2021

Ulcerative colitis

Not definedSuperiorityAcademia2/5 disclosures
Comparisons
1
In the analysis
0
1 withheld
Target trials
1
Emulations reported
3
2 treatments

Comparisons

1 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
Treatment failure, 16 weeks
vs UC SUCCESS·RR·Efficacy
0.770.62–0.96
0.730.60–0.90
not pooled

Design and methods

Estimand
Not defined
Design hypothesis
Superiority
Matching / weighting
1:1 PS matching
Analysis method
Log-binomial regression
Missing data
Complete case
Covariates adjusted
23
DAG
No
QBA
No

Data and sample

Data type
Claims + National Database
Data sources
3
Geography
US, France
Eligible sample
22051
Treated
620
Control
620
Emulations
3
Treatments compared
2

Transparency

2/5
Protocol
No pre-registration
Preprint
No preprint
Conference abstract
https://dx.doi.org/10.1002/pds.5305
Data availability
Unavailable
Code availability
Unavailable
Conflicts of interest
Declared: None
Funding
Declared: Research institute
Funders
The investigators conducted the research independently through funding from internal sources of the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School.

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2021_Kirchgesner_UlcerativeColitis
DOI
https://doi.org/10.1002/pds.5356
Affiliations
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique; AP-HP, Hôpital Saint-Antoine
Sector
Academia
Target trials (study level)
UC SUCCESS
Registration
NCT00537316